Mpox vaccine shows promise for teens in new study
NCT ID NCT05740982
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the JYNNEOS mpox vaccine in 450 healthy teens and adults to see if it works as well in adolescents aged 12-17 as it does in adults. Participants received two shots under the skin. The main goal was to compare immune responses and check for side effects. Results could help expand vaccine access to younger people.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MVA-BN (JYNNEOS) vaccine
What this could lead to
If successful, this could show that the mpox vaccine is safe and effective for adolescents, helping to protect younger people during outbreaks.
What could go wrong
This is a phase 2 trial, so it is still early. The immune response in teens might not match adults, and rare side effects could appear. Results may not apply to all populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONKEYPOX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor College of Medicine
Houston, Texas, 77030-3411, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115-6110, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19146, United States
-
Children's of Alabama Child Health Research Unit (CHRU)
Birmingham, Alabama, 35233-0011, United States
-
Cincinnati Children's Hospital Medical Center Vaccine Research Center
Cincinnati, Ohio, 45229-3039, United States
-
Duke Vaccine and Trials Unit
Durham, North Carolina, 27703, United States
-
Emory University School of Medicine
Atlanta, Georgia, 30322-1014, United States
-
George Washington University Medical Faculty Associates
Washington D.C., District of Columbia, 20037, United States
-
Kaiser Permanente Washington Health Research Institute
Seattle, Washington, 98101-1466, United States
-
NIH Clinical Research Center, Investigational Drug Management and Research Section
Bethesda, Maryland, 20892-1504, United States
-
Ponce Medical School Foundation Inc., CAIMED Center
Ponce, 00716, Puerto Rico
-
Saint Louis University Center for Vaccine Development
St Louis, Missouri, 63104-1015, United States
-
UPMC University Center
Pittsburgh, Pennsylvania, 15213, United States
-
University of Maryland, School of Medicine, Center for Vaccine Development and Global Health
Baltimore, Maryland, 21201-1509, United States
-
University of Rochester Medical Center
Rochester, New York, 14642-0001, United States
-
University of Texas Medical Branch
Galveston, Texas, 77555-0435, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37212, United States
-
Washington University in St. Louis
St Louis, Missouri, 63110-1010, United States